Loading company…
PinotBio develops and manufactures anticancer drugs and antibody-drug conjugates.
Founded in 2017 and based in Suwon, South Korea, PinotBio develops and manufactures anticancer drugs. In October 2025, it raised KRW 13 billion in pre-IPO funding from Mirae Asset Capital, with participation from returning investors KB Investment, Union Investment Partners, BNH Investment, and Mirae Asset Venture Investment. The funding is intended to advance its antibody-drug conjugate pipeline and pursue an IPO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in